Aflibercept (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report was to assess the added benefit of aflibercept in patients with visual impairment due to diabetic macular oedema (DMO).

http://ift.tt/2ssqDoa